Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.

Abstract

OBJECTIVE:

This study was performed to determine the safety and efficacy of belotecan, a new camptothecin analogue and potent topoisomerase I inhibitor, with and without platinum in patients with recurrent ovarian cancer.

METHODS:

Fifty-three patients with recurrent or persistent ovarian cancer were enrolled between March 2005 and March 2008. Eligible patients received 0.5 mg/m of intravenous (IV) belotecan on days 1 to 5, every 3 weeks belotecan monotherapy (B) or 50 mg/m of IV cisplatin on day 1 plus 0.3 mg/m of IV belotecan on days 1 to 5, every 3 weeks (belotecan plus cisplatin combination therapy [BP]).

RESULTS:

Of the 53 treated patients, 34 received BP and 19 received B. Thirty-four patients had platinum-sensitive (PS) disease and 19 had platinum-resistant disease. The overall response of the 53 patients was 37.7% (20/53). According to regimen, the response rate in the BP group was 47.1% (16/34) and that of the B group was 21.1% (4/19). BP had better response (66.7%, 14/21) than B (15.4%, 2/13) for PS disease (P = 0.004), but it was not superior in terms of progression-free survival (BP, 6 month; B, 7 months). Grade 3 or 4 toxicity was less common in B than in BP.

CONCLUSION:

Both BP and B seems to be effective and safe regimens for patients with PS or platinum-resistant recurrent ovarian cancer. These results warrant further prospective randomized trials. Both BP and B seems to be effective and safe regimens for patients with PS or platinum-resistant recurrent ovarian cancer.

• Authors: Eun Ji Nam, Jae Wook Kim, Jae Hoon Kim, Sunghoon Kim, Sang Wun Kim, Si Young Jang, Dae Woo Lee, Yong Wook Jung, Young Tae Kim
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 33 Issue 3 Pg. 233-7 (Jun 2010) ISSN: 1537-453X [Electronic] United States
• PMID: 19745693 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents, Phytogenic
• Organoplatinum Compounds
• belotecan
• Cisplatin
• Camptothecin

Topics

• Adult
• Aged
• Antineoplastic Agents, Phytogenic (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Camptothecin (administration & dosage, analogs & derivatives, therapeutic use)
• Carcinoma (drug therapy, mortality)
• Cisplatin (administration & dosage)
• Disease-Free Survival
• Drug Resistance, Neoplasm
• Female
• Hematologic Diseases (chemically induced)
• Humans
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy)
• Organoplatinum Compounds (administration & dosage)
• Ovarian Neoplasms (drug therapy, mortality)
• Salvage Therapy
• Survival Analysis
• Treatment Outcome